Selective targeting of FAK–Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells

Datta, Amrita; Bhasin, Nobel; Kim, Hogyoung; Ranjan, Manish; Rider, Barbara J.; Elmageed, Zakaria Y. Abd; Mondal, Debasis; Agrawal, Krishna C.; Abdel‐Mageed, Asim B.

doi:10.1016/j.canlet.2015.03.009

Cited by 28 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, tumor volume appeared as explosive growth for injecting free DOX or GION-DOX to mice, which was ascribed to resistant drug of cancer cells. [ 40,41 ] In contrast, FA-GION-DOX displayed a signifi cant inhibitory effect in tumor size, which may be mainly due to the sustained DOX release in vivo in the tumor tissue after particle accumulation via targeting effect of folic acid. Images of Figure 6 b were consistent with Figure 6 a, showing that FA-GION-DOX possessed a stronger inhibitory effect on tumor growth.…”

Section: Antitumor Effect In a Subcutaneous Human Cervical Cancer Xenmentioning

confidence: 94%

Gadolinium‐Doped Iron Oxide Nanoprobe as Multifunctional Bioimaging Agent and Drug Delivery System

Zhang

et al. 2015

Adv Funct Materials

View full text Add to dashboard Cite

In this study, a high-performance T 1 -T 2 dual-model contrast agent by gadolinium-doped iron oxide nanoparticle (GION) is developed. Following its development, the application of this agent in vivo by combining doxorubicin (DOX) and folic acid (FA) (FA-GION-DOX) for targeted drug delivery to monitor cancer treatment is explored. GION showed transverse and longitudinal relaxivities up to 182.7 × 10 −3 and 7.87 × 10

show abstract

Section: Antitumor Effect In a Subcutaneous Human Cervical Cancer Xenmentioning

confidence: 94%

Gadolinium‐Doped Iron Oxide Nanoprobe as Multifunctional Bioimaging Agent and Drug Delivery System

Zhang

et al. 2015

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…The experiments were performed as we described [15]. Briefly, a panel of control (RWPE-1) and CRPC (C4-2B, PC-3, and 22Rv1) cells were seeded in a 96-well plate and treated with MA at a concentration range of 0 (DMSO vehicle) to 250 nM in triplicates for 48 h. Fresh media containing 0.5 mg/ml MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] was then added for 4 h. The supernatants were removed and the resulting formazan crystals were solubilized in DMSO and measured at 570 nm using a BioTek microplate reader (BioTek, Winooski, VT).…”

Section: Methodsmentioning

confidence: 99%

Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells

et al. 2017

Self Cite

View full text Add to dashboard Cite

Emerging evidence links exosomes to cancer progression by the trafficking of oncogenic factors and neoplastic reprogramming of stem cells. This necessitates identification and integration of functionally validated exosome-targeting therapeutics into current cancer management regimens. We employed quantitative high throughput screen on two libraries to identify exosome-targeting drugs; a commercially available collection of 1280 pharmacologically active compounds and a collection of 3300 clinically approved compounds. Manumycin-A (MA), a natural microbial metabolite, was identified as an inhibitor of exosome biogenesis and secretion by castration-resistant prostate cancer (CRPC) C4-2B, but not the normal RWPE-1, cells. While no effect was observed on cell growth, MA attenuated ESCRT-0 proteins Hrs, ALIX and Rab27a and exosome biogenesis and secretion by CRPC cells. The MA inhibitory effect is primarily mediated via targeted inhibition of the Ras/Raf/ERK1/2 signaling. The Ras-dependent MA suppression of exosome biogenesis and secretion is partly mediated by ERK-dependent inhibition of the oncogenic splicing factor hnRNP H1. Our findings suggest that MA is a potential drug candidate to suppress exosome biogenesis and secretion by CRPC cells.

show abstract

“…PYK2 is a cytoplasmic tyrosine kinase of the focal adhesion kinase subfamily (Fan and Guan 2011). PYK2 promotes cell migration and drug resistance in many tumor types including hepatocellular and breast cancer and is activated by the PI3K/Akt signaling pathway (Datta et al 2015;Geng et al 2011). PYK2 mRNA and protein were detected in recipient cells after co-culture with the MDR counterpart cell line, although PYK2 was not detected in MPs.…”

Section: Pyk2 Regulation By Cd44 Mir-494 and Mir-303-3pmentioning

confidence: 87%

Membrane microparticles: shedding new light into cancer cell communication

Souza

Faccion

Bernardo³

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

This review summarizes recent findings on MP biogenesis and the role of the MPs cargo in cancer and discusses some of the RNAs and proteins involved. In addition, the discussion covers evidence of (1) how and which signaling pathways can be activated by MPs in recipient cells; (2) recipient cell-type selectivity in incorporation of proteins and RNAs transported by MPs; and (3) how upon stimulation, stromal cells release MPs, promoting resistance to chemotherapeutics and invasiveness in cancer cells.

show abstract

Selective targeting of FAK–Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells

Cited by 28 publications

References 47 publications

Gadolinium‐Doped Iron Oxide Nanoprobe as Multifunctional Bioimaging Agent and Drug Delivery System

Gadolinium‐Doped Iron Oxide Nanoprobe as Multifunctional Bioimaging Agent and Drug Delivery System

Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells

Membrane microparticles: shedding new light into cancer cell communication

Contact Info

Product

Resources

About